Liquidia Corp (NASDAQ:LQDA) on Monday reported better-than-expected first-quarter financial results.
Liquidia reported quarterly earnings of 52 cents per share which beat the analyst consensus estimate of 41 cents per share. The company reported quarterly sales of $132.865 million which beat the analyst consensus estimate of $116.675 million.
Dr. Roger Jeffs, Liquidia’s Chief Executive Officer, said, “In its third full quarter on the market, YUTREPIA continued to demonstrate sustained uptake in pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), consistent with its growing adoption as the preferred inhaled prostacyclin of choice. Having initiated additional Phase 4 studies of YUTREPIA and our pivotal Phase 3 Re-Spire study of L606, our focus in 2026 is on making the full benefit of prostacyclin therapy available to more patients who need it, across a broader set of serious pulmonary and vascular diseases where high unmet need remains prevalent.”
Liquidia shares gained 3.1% to trade at $54.80 on Tuesday.
These analysts made changes to their price targets on Liquidia following earnings announcement.
- Wells Fargo analyst Benjamin Burnett maintained the stock with an Overweight rating and raised the price target from $51 to $62.
- HC Wainwright & Co. analyst Andrew S. Fein maintained the stock with a Buy and raised the price target from $55 to $67.
Considering buying LQDA stock? Here’s what analysts think:
Photo via Shutterstock